{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:57:19Z","timestamp":1779299839990,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijantimicag.2020.106178","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T09:37:03Z","timestamp":1601026623000},"page":"106178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-5350","authenticated-orcid":false,"given":"Justin A.","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Kulengowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106178_bib0001","unstructured":"US Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. http:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf[accessed 5\/12\/2015]."},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0002","unstructured":"US Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf [accessed 01\/05\/2020]."},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of ceftazidime\u2013avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0004","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/jac\/dkz468","article-title":"In vitro selection of aztreonam\/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae","volume":"75","author":"Niu","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0005","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cis270","article-title":"Excess deaths associated with tigecycline after approval based on noninferiority trials","volume":"54","author":"Prasad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0006","series-title":"TYGACIL (tigecycline) [package insert]","year":"2016"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0007","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0008","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/jac\/dkq210","article-title":"A simple phenotypic method for the differentiation of metallo-\u03b2-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates","volume":"65","author":"Tsakris","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0009","series-title":"Eravacycline\u2013injection products. FDA-identified interpretive criteria.","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0010","series-title":"Tigecycline\u2013injection products. FDA-identified interpretive criteria","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0011","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1207\/S15327906MBR3404_2","article-title":"The bootstrap, the jackknife, and the randomization test: a sampling taxonomy","volume":"34","author":"Rodgers","year":"1999","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0012","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0013","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: the tetracyclines strike back","volume":"53","author":"Heaney","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0014","series-title":"American Society for Microbiology (ASM) Microbe 2018","article-title":"Global in vitro activity of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Staphylococcus aureus and Enterococcus spp. including multidrug-resistant (MDR) isolates from 2016","author":"Lawrence","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0015","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In-vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0016","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ja.2016.73","article-title":"In vitro susceptibility of \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline","volume":"69","author":"Zhang","year":"2016","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0017","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0018","series-title":"Center for Drug Evaluation and Research. Xerava (eravacycline) NDA\/BLA multi-disciplinary review and evaluation","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0019","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2016.12.008","article-title":"A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding","volume":"49","author":"Singh","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0020","unstructured":"United States Committee on Antimicrobial Susceptibility Testing (USCAST). Breakpoint tables for interpretation of MIC and zone diameter results. Version 5.3, 2019. https:\/\/app.box.com\/s\/cru62wluz4qq64vd5izk41wle9ss172x [accessed 25 September 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106178_bib0021","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf [accessed 25 September 2020]."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:46Z","timestamp":1760377066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920303848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0924857920303848"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106178","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106178"}}